-
Citi Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
Arcturus Therapeutics to Attend Upcoming Investor Conferences
-
Citi Upgrades Arcturus Therapeutics (ARCT) to Buy
-
Arcturus Therapeutics to Attend the Following Investor Conferences
-
UPDATE: Citi Downgrades Arcturus Therapeutics (ARCT) to Neutral
-
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
-
Pre-Open Stock Movers 12/08: (LXRX) (SFIX) (SMAR) Higher; (PEN) (CONN) (MRNS) Lower (more...)
-
UPDATE: Citi Starts Arcturus Therapeutics (ARCT) at Buy
-
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Arcturus Therapeutics (ARCT) Prices 3.26M Share Common Offering at $53/Sh
-
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
-
Arcturus Therapeutics (ARCT) Announces Proposed Public Offering of Common Stock
-
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
-
Pre-Open Stock Movers 04/16: (RCUS) (LOVE) (BBBY) Higher; (DO) (RAD) (ATHX) Lower (more...)
-
After-Hours Stock Movers 04/15: (RCUS) (AM) (BBBY) Higher; (ATHX) (CALA) (LAKE) Lower (more...)

